Funding to Propel Innovative Cancer Treatments
Captain T Cell, a pioneering biotechnology firm, has successfully completed a significant financing round aimed at advancing its next-generation TCR-T cell therapies for solid tumors. This recent funding effort has raised a total of EUR 20 million, solidifying the company's ability to proceed with clinical trial preparations for its groundbreaking treatments.
Key Investors Highlight Strong Confidence
The financing round saw active participation from prominent investors, including Springboard Health Angels and Pluton Asset Holding AG, with participation from Sintra Limited and Technologiegründerfonds Sachsen. Existing supporters such as i&i Biotech Fund, HIL-INVENT, and Brandenburg Kapital also contributed, illustrating a robust belief in Captain T Cell’s potential to transform cancer treatment.
Advancing Towards Clinical Trials
The influx of capital will enable Captain T Cell to progress its lead program, CTC127, into a first-in-human Phase I clinical trial. This trial, known as TOMATA, aims to evaluate the safety and effectiveness of customized T cell therapy targeting MAGE-A4, a protein associated with various solid tumors. Under the guidance of Prof. Antonia Busse from Charité – Universitaetsmedizin Berlin, the trial will include participation from multiple leading cancer centers across Germany, enrolling patients diagnosed with advanced MAGE-A4-positive cancers.
Innovative Approaches to Cancer Therapy
Captain T Cell is dedicated to addressing critical challenges in treating solid tumors through its innovative technology toolbox, which significantly enhances the T cell efficacy within the challenging tumor microenvironment. By armoring these T cells, the company aims to bolster their persistence and efficacy, leading to improved patient outcomes.
Expanding the Therapeutic Landscape
In conjunction with the efforts toward CTC127, Captain T Cell has reported promising results from preliminary studies of its allogeneic TCR-T cell platform, which has shown complete tumor responses in animal models. The company plans to propel this program toward clinical readiness, aiming to offer off-the-shelf therapy options for patients in need.
CEO's Perspective on Future Prospects
Dr. Felix Lorenz, CEO of Captain T Cell, expressed optimism regarding the financing round and the substantial backing received. He emphasized that despite challenging market conditions, the strong investor support is a testament to the competitive advantage of the company’s therapeutic platform. "Our autologous program CTC127 will enter the TOMATA clinical trial, marking a significant milestone in our mission to provide innovative treatments for cancer patients,” he stated.
Optimism from Investors
Investor insights further bolster confidence in Captain T Cell's advancements. Dr. Andreas Schmidt of Springboard Health Angels noted the immense potential of CTC127 as a transformative treatment for solid tumors, providing necessary hope for patients in need of effective therapies. Furthermore, industry experts recognize MAGE-A4 as a reliable target, enhancing the validation of Captain T Cell's innovative strategies.
About Captain T Cell
Founded as a spinoff from the Max Delbrück Center for Molecular Medicine, Captain T Cell is focused on developing next-generation immunotherapies designed to improve patient outcomes in oncology. Their proprietary technology is aimed at enhancing T cell performance against solid tumors, with their lead program targeting MAGE-A4-positive diseases. The company is actively working towards entering clinical trials within a competitive timeframe.
Frequently Asked Questions
What is Captain T Cell currently focusing on?
Captain T Cell is primarily working on developing next-generation TCR-T therapies for solid tumors, particularly their lead program CTC127, which targets MAGE-A4-positive cancers.
How much funding has Captain T Cell secured?
The company recently secured EUR 20 million in funding to advance its clinical research and development efforts.
When will the clinical trials for CTC127 begin?
Captain T Cell is preparing to enter the Phase I clinical trial for CTC127, known as TOMATA, expected to start in the near future.
Who are the main investors behind Captain T Cell?
Key investors include Springboard Health Angels, Pluton Asset Holding AG, Sintra Limited, and Technologiegründerfonds Sachsen, among other existing investors.
What are the future plans for Captain T Cell?
In addition to advancing CTC127, Captain T Cell plans to build upon its technology toolbox to develop various novel therapies for cancer treatment.
